Literature DB >> 2068575

Urticarial vasculitis in a connective tissue disease clinic: patterns, presentations, and treatment.

R A Asherson1, D D'Cruz, C J Stephens, P H McKee, G R Hughes.   

Abstract

Findings in 27 patients with typical skin lesions of urticarial vasculitis (UV) who were seen at a connective tissue disease clinic over a 5-year period (1986 to 1990) are reviewed. The majority suffered from systemic lupus erythematosus (SLE) or from "lupus-like" disease (18 patients), 1 from "mixed" connective tissue disease (MCTD), and 5 from primary UV. All of the latter patients had normal serum complement levels (normocomplementemic urticarial vasculitic syndrome; NUVS). No patients with hypocomplementemic UV were encountered. Two patients suffered from necrotizing vasculitis (polyarteritis nodosa, Wegener's granulomatosis); one had a C1-esterase inhibitor deficiency and also demonstrated an immunoglobulin G paraproteinemia. Angioedema occurred in many patients and could not be used as a differential diagnostic feature. The course of the illness was chronic in most patients, lasting for up to 23 years, and the response to therapy was unpredictable, erratic, and unsustained. The use of intravenous "pulse" methylprednisolone, cyclophosphamide, or high-dose oral steroids helped selected patients. Colchicine was dramatically effective in one patient with NUVS of 15 years duration. Azathioprine was not beneficial. None of the five patients with NUVS suffered from severe systemic involvement or renal disease, confirming observations by others that this form of UV represents a milder example of the condition.

Entities:  

Mesh:

Year:  1991        PMID: 2068575     DOI: 10.1016/0049-0172(91)90029-y

Source DB:  PubMed          Journal:  Semin Arthritis Rheum        ISSN: 0049-0172            Impact factor:   5.532


  8 in total

Review 1.  Urticarial vasculitis and syndromes in association with connective tissue diseases.

Authors:  R A Asherson; R Sontheimer
Journal:  Ann Rheum Dis       Date:  1991-11       Impact factor: 19.103

Review 2.  Treatment of vasculitis.

Authors:  H G Taylor; A Samanta
Journal:  Br J Clin Pharmacol       Date:  1993-02       Impact factor: 4.335

Review 3.  Urticarial vasculitis.

Authors:  Joe Venzor; Wai L Lee; David P Huston
Journal:  Clin Rev Allergy Immunol       Date:  2002-10       Impact factor: 8.667

Review 4.  Chronic urticaria.

Authors:  A Leznoff
Journal:  Can Fam Physician       Date:  1998-10       Impact factor: 3.275

5.  Acute transverse myelitis and primary urticarial vasculitis.

Authors:  G Bolla; P Disdier; D Verrot; L Swiader; L Andrac; J R Harlé; J Pouget; P J Weiller
Journal:  Clin Rheumatol       Date:  1998       Impact factor: 2.980

6.  Bilateral pleural effusion in a patient with urticarial vasculitis.

Authors:  S O Paira
Journal:  Clin Rheumatol       Date:  1994-09       Impact factor: 2.980

7.  Systemic Lupus Erythematosus Vasculitis: A Current Therapeutic Overview.

Authors:  Elias Toubi; Aharon Kessel; Ellen Bamberger; Theo Dov Golan
Journal:  Curr Treat Options Cardiovasc Med       Date:  2004-04

Review 8.  Uncommon features of polyarteritis nodosa: psychosis and angio-oedema.

Authors:  S R Fernandes; I B Coimbra; L T Costallat; J E Ribeiro Filho
Journal:  Clin Rheumatol       Date:  1998       Impact factor: 2.980

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.